AORT · Artivion, Inc.
$25.00
-0.56% last session
End-of-day data · updated 2026-07-25
Market cap
$1B
Enterprise value
$1B
Trailing P/E
101.1
Forward P/E
35.1
Dividend yield
—
Beta
1.25
Avg volume
1M
Employees
2K
2D change
1.12%
5D change
-0.35%
10D change
3.99%
30D change
11.56%
60D change
9.01%
MTD change
7.35%
YTD change
-44.57%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — AORT
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-07-20
Latest call per bank · past 12 months
Recent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-07-20 | Needham | Reiterates | Buy | $44.00 |
| 2026-06-16 | Canaccord Genuity | Maintains | Buy | $36.00 |
| 2026-05-08 | Citizens | Maintains | Market Outperform | $53.00 → $48.00 |
| 2026-05-08 | Needham | Maintains | Buy | $58.00 → $44.00 |
| 2026-04-10 | Ladenburg Thalmann | Upgrade | Neutral → Buy | $0.00 → $42.00 |
| 2026-04-07 | Needham | Reiterates | Buy | $58.00 |
| 2026-02-13 | Canaccord Genuity | Maintains | Buy | $51.00 → $48.00 |
| 2026-02-02 | Needham | Reiterates | Buy | $58.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-23
- RSI (14): RSI is 56 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 10.5% above the 50-day MA ($22.63).
- Price vs 200-day MA: Trading 31.1% below the 200-day MA ($36.30).
- MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
- MACD (12,26,9): MACD histogram is positive (+0.18) — short-term momentum is improving.
- 52-week range: Price sits between the 52-week low ($20.10) and high ($47.63).
AORT Price Chart
Loading chart for AORT…
Fundamentals
About Artivion, Inc.
Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers On-X prosthetic aortic and mitral heart valves; On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters; Chord-X ePTFE sutures; pyrolytic carbon coating services; E-vita Open NEO, a hybrid stent graft; Arcevo, an LSA hybrid stent graft system; AMDS hybrid prosthesis; and NEXUS ONE, an endovascular stent graft system. It also provides NEXUS DUO, an aortic arch system; NEXUS TRE, a custom-made three branch graft; E-vita thoracic 3G, a stent graft system; E-xtra Design Engineering, a range of stent graft systems for the treatment of aortic vascular diseases, such as TAAA and Artivex; E-nside, a multibranch stent graft system; E-tegra, an AAA stent graft system; E-ventus BX and Tuva BX balloon-expandable peripheral stent grafts; and E-liac, a stent graft used to treat aneurysmal iliac arteries. In addition, the company offers synthetic vascular grafts that are used in open aortic and peripheral vascular surgical procedures; BioGlue, a surgical sealant; CryoValve SG pulmonary heart valve; CryoPatch SG pulmonary cardiac patch; SynerGraft, a decellularization technology; vascular preservation services; and PhotoFix, a bovine pericardial patch fixated. It markets its products and preservation services primarily to physicians through a direct sales team to hospitals and other healthcare facilities. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.
More in Medical Devices
ABT
Abbott Laboratories
$180B -16.2% YTD
SYK
Stryker Corporation
$127B -5.5% YTD
MDT
Medtronic plc.
$107B -11.9% YTD
BSX
Boston Scientific Corporation
$66B -53.6% YTD
EW
Edwards Lifesciences Corporatio
$48B -3.1% YTD
GEHC
GE HealthCare Technologies Inc.
$28B -26.1% YTD
DXCM
DexCom, Inc.
$28B 7.8% YTD
PHG
Koninklijke Philips N.V. NY Reg
$25B 0.4% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.